Hundreds of injections for diabetes or weight loss like Ozempic, Wegovy or Mounjaro reported to have acute or chronic pancreatitis in the United Kingdom.
• Read also: Ozempic would reduce the desires to consume alcohol
• Read also: The Ozempic to fight against infantile obesity? New recommendations moving away from “eating less, moving more”
In front of this number, the Medicines and Health Regulatory Agency (MHRA) asked people on Thursday who were hospitalized due to acute pancreatitis to contact them to conduct a study.
The British government agency will try, with these data, to establish whether the pancreatitis suspected of being linked to GLP-1, or Peptide-1 type injections, for weight loss or the treatment of type 2 diabetes, could be influenced by a person’s genes, according to a statement published Thursday.
The MHRA indicated that 181 cases of acute or chronic pancreatitis, linked to the hormone used by the injections of Mounjaro (shooting), were reported, five of which resulted in death, according to Sky News.
The media also reports that 113 cases of acute or chronic pancreatitis, linked to the hormone used in the injections of Ozempic and Wegovy (Semaglutide), were recorded by the health agency, and that a person would have died.
More than a quarter of the 400 cases recorded by the MHRA were reported in 2025, according to The Guardian .
